Profile data is unavailable for this security.
About the company
Estrella Immunopharma, Inc. is a preclinical-stage biopharmaceutical company. The Company is developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Its lead product candidate, EB103, utilizes Eureka's ARTEMIS technology to target CD19, a protein expressed on the surface of almost all B-cell leukemias and lymphomas. The Company is also developing EB104, which also utilizes Eureka's ARTEMIS technology to target not only CD19, but also CD22, a protein that, like CD19, is expressed on the surface of most B-cell malignancies. The Company is also collaborating with Imugene Limited and its product candidate, CF33-CD19t an oncolytic virus (CF33-CD19t), to research the use of EB103 in conjunction with CF33-CD19t to treat solid tumors.
- Revenue in USD (TTM)0.00
- Net income in USD-2.16m
- Incorporated2021
- Employees--
- LocationEstrella Immunopharma Inc5858 Horton Street, Suite 370EMERYVILLE 94608United StatesUSA
- Phone+1 (510) 318-9098
- Fax+1 (847) 827-5303
- Websitehttps://www.estrellabio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Palatin Technologies, Inc. | 7.10m | -30.91m | 36.95m | 34.00 | -- | -- | -- | 5.21 | -2.48 | -2.48 | 0.5582 | -0.7956 | 0.3118 | 0.8717 | 3.42 | 208,755.90 | -135.79 | -26.11 | -269.84 | -30.68 | 95.34 | -- | -435.53 | -126.20 | 1.09 | -- | -- | -- | 230.53 | -40.87 | 23.91 | -- | 80.82 | -- |
| SAB Biotherapeutics Inc | 2.24m | -42.19m | 36.99m | 57.00 | -- | 0.6456 | -- | 16.52 | -7.18 | -7.18 | 0.4056 | 6.21 | 0.0332 | -- | 0.8059 | 39,280.53 | -62.58 | -- | -77.39 | -- | -- | -- | -1,884.50 | -- | -- | -- | 0.0743 | -- | -90.63 | -- | -125.14 | -- | -- | -- |
| Sensei Biotherapeutics Inc | 0.00 | -34.10m | 37.87m | 27.00 | -- | 0.5824 | -- | -- | -1.21 | -1.21 | 0.00 | 2.59 | 0.00 | -- | -- | 0.00 | -35.38 | -47.03 | -38.31 | -54.33 | -- | -- | -- | -- | -- | -- | 0.0247 | -- | -- | -- | 29.82 | -- | 42.16 | -- |
| Aspira Women's Health Inc | 9.15m | -16.69m | 38.22m | 64.00 | -- | -- | -- | 4.18 | -1.73 | -1.73 | 0.9683 | -0.2222 | 0.7746 | 14.34 | 6.77 | 143,031.30 | -141.23 | -110.58 | -256.99 | -151.88 | 57.48 | 45.23 | -182.32 | -334.08 | 0.9871 | -- | -- | -- | 11.85 | 24.56 | 44.15 | -- | -26.65 | -- |
| OncoCyte Corp | 1.50m | -25.80m | 38.62m | 43.00 | -- | 1.17 | -- | 25.70 | -3.08 | -3.47 | 0.1869 | 3.10 | 0.0172 | -- | 1.20 | 34,953.49 | -28.41 | -35.11 | -31.93 | -39.71 | 27.48 | -- | -1,653.69 | -2,373.36 | -- | -146.07 | 0.00 | -- | 56.89 | -- | -34.84 | -- | 55.41 | -- |
| Vyne Therapeutics Inc | 423.00k | -28.51m | 38.79m | 10.00 | -- | 0.458 | -- | 91.70 | -5.26 | -5.43 | 0.021 | 5.83 | 0.0067 | -- | -- | 42,300.00 | -35.07 | -108.41 | -39.58 | -138.57 | -- | -- | -5,262.65 | -1,907.10 | -- | -- | -- | -- | -11.11 | -47.51 | 17.89 | -- | -- | -- |
| Cara Therapeutics Inc | 20.97m | -118.51m | 39.12m | 55.00 | -- | 0.6830 | -- | 1.87 | -2.19 | -2.19 | 0.3872 | 1.05 | 0.1361 | 2.37 | 6.96 | 381,236.40 | -76.94 | -35.76 | -91.50 | -40.82 | 70.56 | -- | -565.21 | -162.10 | 4.43 | -- | 0.00 | -- | -49.92 | 9.26 | -38.65 | -- | 100.66 | -- |
| Unicycive Therapeutics Inc | 675.00k | -31.41m | 39.27m | 14.00 | -- | -- | -- | 58.18 | -1.62 | -1.62 | 0.0276 | -0.1096 | 0.0794 | -- | -- | 48,214.29 | -359.15 | -218.20 | -- | -609.54 | -- | -- | -4,525.04 | -3,877.49 | -- | -- | -- | -- | -29.02 | -- | -73.95 | -- | -- | -- |
| Eyenovia Inc | 3.79k | -27.26m | 39.30m | 57.00 | -- | 3.90 | -- | 10,370.40 | -0.6639 | -0.6639 | 0.00009 | 0.1976 | 0.0001 | -- | 0.0031 | 66.49 | -91.15 | -80.31 | -119.11 | -117.70 | 0.00 | -- | -719,290.30 | -680.95 | 2.16 | -15.14 | 0.6135 | -- | -- | -- | 2.68 | -- | 152.20 | -- |
| Estrella Immunopharma Inc | 0.00 | -2.16m | 39.54m | -- | -- | 3.78 | -- | -- | -1.90 | -1.90 | 0.00 | 0.2861 | 0.00 | -- | -- | -- | -5.92 | -- | -7.86 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -302.11 | -- | -- | -- |
| Bright Green Corp | 0.00 | -13.13m | 40.30m | 5.00 | -- | 3.57 | -- | -- | -0.0732 | -0.0732 | 0.00 | 0.0594 | 0.00 | -- | -- | 0.00 | -64.24 | -- | -97.68 | -- | -- | -- | -- | -- | -- | -5,488.51 | 0.0181 | -- | -- | -- | 52.54 | -- | -- | -- |
| Incannex Healthcare Inc | 163.39k | -13.70m | 40.32m | -- | -- | 2.14 | -- | 246.76 | -0.3806 | -0.3806 | 0.0003 | 1.19 | 0.0038 | -- | 0.0554 | -- | -31.42 | -54.94 | -32.90 | -59.47 | -- | -- | -8,386.19 | -1,033.07 | -- | -- | 0.00 | -- | 61.92 | 3.38 | -24.35 | -- | 54.12 | -- |
| Natural Alternatives International, Inc. | 127.76m | -4.11m | 40.61m | 317.00 | -- | 0.4753 | 90.25 | 0.3179 | -0.705 | -0.705 | 21.87 | 14.03 | 0.8624 | 4.23 | 12.32 | 403,041.00 | -2.77 | 4.90 | -3.11 | 5.93 | 7.90 | 15.98 | -3.22 | 3.80 | 2.59 | -2.54 | 0.0988 | 0.00 | -9.91 | 3.06 | -76.46 | -20.74 | 27.08 | -- |
| Quince Therapeutics Inc | 0.00 | -31.39m | 41.05m | 32.00 | -- | 0.4798 | -- | -- | -0.8424 | -0.8424 | 0.00 | 1.98 | 0.00 | -- | -- | 0.00 | -23.09 | -42.72 | -24.22 | -46.06 | -- | -- | -- | -- | -- | -- | 0.1363 | -- | -- | -- | 39.25 | -- | -5.47 | -- |
| Cyclo Therapeutics Inc | 1.08m | -20.06m | 42.21m | 8.00 | -- | 8.82 | -- | 39.22 | -1.33 | -1.33 | 0.0679 | 0.1666 | 0.1233 | 0.387 | 12.14 | 134,551.30 | -229.72 | -132.22 | -727.50 | -215.17 | 90.85 | 90.37 | -1,863.35 | -1,114.04 | 1.42 | -2,769.34 | 0.00 | -- | -21.76 | 1.25 | -29.81 | -- | -3.95 | -- |
Data as of May 10 2024. Currency figures normalised to Estrella Immunopharma Inc's reporting currency: US Dollar USD
0.35%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Geode Capital Management LLCas of 31 Dec 2023 | 56.22k | 0.15% |
| ATW SPAC Management LLCas of 31 Dec 2023 | 40.00k | 0.11% |
| Hunting Hill Global Capital LLCas of 31 Dec 2023 | 21.36k | 0.06% |
| Maso Capital Partners Ltd.as of 31 Mar 2024 | 10.00k | 0.03% |
| Tower Research Capital LLCas of 31 Dec 2023 | 632.00 | 0.00% |
| UBS Securities LLCas of 31 Dec 2023 | 303.00 | 0.00% |
| Wells Fargo Bank, NA (Private Banking)as of 31 Mar 2024 | 74.00 | 0.00% |
| Jane Street Capital LLCas of 31 Dec 2023 | 0.00 | 0.00% |
| Owl Creek Asset Management LPas of 31 Dec 2023 | 0.00 | 0.00% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
